2021
Short and long term outcomes of cardiac amyloidosis patients listed for heart transplantation in the united states: a propensity-matched analysis
Akintoye E, Alvarez P, Briasoulis A. Short and long term outcomes of cardiac amyloidosis patients listed for heart transplantation in the united states: a propensity-matched analysis. European Heart Journal 2021, 42: ehab724.0965. DOI: 10.1093/eurheartj/ehab724.0965.Peer-Reviewed Original ResearchPost-transplant graft survivalGraft survivalGraft survival ratesPropensity-matched analysisCA patientsHigher waitlist mortalityHeart transplantationCardiac amyloidosis patientsWaitlist mortalityRestrictive cardiomyopathyRisk factorsDonor heartsAmyloidosis patientsSurvival rateStudy periodComparable graft survivalPoor graft survivalPropensity-matched cohortOrgan Sharing databaseSingle-center experienceCohort of patientsPredictors of survivalLong-term outcomesSignificant risk factorsAmyloid recurrence
2020
TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients
Moshe-Lilie O, Dimitrova D, Heitner S, Brannagan T, Zivkovic S, Hanna M, Masri A, Polydefkis M, Berk J, Gertz M, Karam C. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients. Amyloid 2020, 27: 250-253. PMID: 32578459, DOI: 10.1080/13506129.2020.1784134.Peer-Reviewed Original ResearchConceptsHereditary transthyretin (TTR) amyloidosisGene silencing therapySilencing therapyMedian duration of therapyPatients stopped treatmentDuration of therapyATTR amyloidosis patientsBone marrow functionNeuropathy Impairment ScoreATTR amyloid depositsOrthotopic liver transplantationTTR gene silencingMedian durationMarrow functionMedian ageAmyloidosis patientsDiscontinued treatmentFrequent complicationMedian timeLiver rejectionLiver transplantationTreatment optionsDisease progressionGene silencing agentsPatients
1999
Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis
COMENZO R, SANCHORAWALA V, FISHER C, AKPEK G, FARHAT M, CERDA S, BERK J, DEMBER L, FALK R, FINN K, SKINNER M, VOSBURGH E. Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis. British Journal Of Haematology 1999, 104: 553-559. PMID: 10086794, DOI: 10.1046/j.1365-2141.1999.01216.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmyloidosisAntineoplastic Agents, AlkylatingDrug CombinationsFemaleGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousLeukapheresisMaleMelphalanMiddle AgedSurvival AnalysisConceptsBlood stem cellsMobilization regimensG-CSFIntermediate dose (15-30 mg/m2, day 1) intravenous melphalanDose-intensive melphalanPhase 11 trialGrade 4 toxicityComplete haematological responseCells/AL amyloidosis patientsTerms of CD34Stem cellsActive regimenMobilization patientsDose melphalanOrgan involvementIntravenous melphalanCardiac amyloidD mortalityMonths 57AL amyloidosisAmyloidosis patientsHaematological responsePatientsDay 5
1998
Echocardiographic identification of cardiac amyloidosis patients capable of undergoing intensive treatment with intravenous melphalan therapy
Mendes L, Reisinger J, Dubrey S, Comenzo R, Vosburgh E, Sanchorawala V, LaValley M, Skinner M, Falk R. Echocardiographic identification of cardiac amyloidosis patients capable of undergoing intensive treatment with intravenous melphalan therapy. Journal Of The American College Of Cardiology 1998, 31: 109. DOI: 10.1016/s0735-1097(98)81120-0.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply